Adverse events (Grade 1–5) by system organ class among Black participants in HVTN 503.

Figshare2021-01-22 更新2026-04-28 收录

数据链接：

https://figshare.com/articles/dataset/Adverse_events_Grade_1_5_by_system_organ_class_among_Black_participants_in_HVTN_503_/13629365 数据链接链接失效反馈

官方服务：

资源简介：

Adverse events (Grade 1–5) by system organ class among Black participants in HVTN 503.

创建时间：

2021-01-22

Data from: Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ Lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial

疫苗临床试验

免疫反应

Background: Novel tuberculosis vaccines should be safe, immunogenic, and effective in various population groups, including HIV-infected individuals. In this phase II multi-centre, double-blind, placeb

DataONE2014-12-22 更新160

ATN 064 Cervical Cytology Specimen Dataset in Immunogenicity, Safety, Tolerability, and Behavioral Consequences of an HPV-6, -11, -16, -18 Vaccine in HIV-Infected Young Women

疫苗临床试验

HIV感染人群免疫评估

Data from Cervical Cytology History Form: Type Collected [CRF 13, question 4] Study Description A Phase II, open-label, multi-center study that evaluated the immunogenicity, safety, tolerability, and

NIAID Data Ecosystem50

Characteristics of HVTN 502 and 503 trial participants.

疫苗临床试验

免疫基因型分析

Data shown are median values (interquartile range) unless otherwise indicated. * At time of sampling § HLA-B*27, B51, B*5701/03, B*5801 and B*8101 Characteristics of HVTN 502 and 503 trial participant

NIAID Data Ecosystem20

DataSheet_1_Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.docx

癌症免疫治疗

疫苗临床试验

BackgroundImmune checkpoint blockade with monoclonal antibodies targeting programmed death 1 (PD-1) and its ligand PD-L1 has played a major role in the rise of cancer immune therapy. We have identifie

NIAID Data Ecosystem70

ATN 064 Burk HPV DNA Dataset in Immunogenicity, Safety, Tolerability, and Behavioral Consequences of an HPV-6, -11, -16, -18 Vaccine in HIV-Infected Young Women

疫苗临床试验

HIV感染者免疫干预

Burk Lab HPV DNA data Study Description A Phase II, open-label, multi-center study that evaluated the immunogenicity, safety, tolerability, and behavioral impact of an HPV-6, -11, -16, -18 vaccine in

NIAID Data Ecosystem40

Adverse events (Grade 1–5) by system organ class among Black participants in HVTN 503.

资源简介：

相关数据集